ArticleAntimicrobial agents and chemotherapy2009
Pharmacokinetics of high-dose oseltamivir in healthy volunteers.
Article in Antimicrobial agents and chemotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01049763 (Phase I, Open-Label Study to Evaluate Potential Pharmacokinetic of Orally Administered Oseltamivir in Healthy Obese Thai Adult Subjects), which is not on this map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I, Open-Label Study to Evaluate Potential Pharmacokinetic of Orally Administered Oseltamivir in Healthy Obese Thai Adult Subjects
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- How Feasible is the Use of Saliva for Antiviral Therapeutic Drug Monitoring? A Systematic Review and Analysis.Clinical pharmacokinetics · 2026Pooled it
- Role of the ABCB1 Drug Transporter Polymorphisms in the Pharmacokinetics of Oseltamivir in Humans: a Preliminary Report.Journal of Korean medical science · 2017Trial
- Effects of alcohol on human carboxylesterase drug metabolism.Clinical pharmacokinetics · 2015Trial
- Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects.Antimicrobial agents and chemotherapy · 2014Trial
- Pharmacokinetics and diffusion into sputum of oseltamivir and oseltamivir carboxylate in adults with cystic fibrosis.Antimicrobial agents and chemotherapy · 2011Trial
- An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults.Antimicrobial agents and chemotherapy · 2011Trial
- A novel ursodeoxycholic acid derivative exhibits broad-spectrum antiviral activity against influenza A virus and coronaviruses by multiphasic disruption of the viral life cycle.Antimicrobial agents and chemotherapy · 2026Article
- Pharmacologic background and clinical issue of anti-influenza drugs.Fukushima journal of medical science · 2025Review
- Oseltamivir-induced hepatotoxicity: A retrospective analysis of the FDA adverse event reporting system.PloS one · 2025Article
- Article
- Article
- Metabolism and disposition of oseltamivir (OS) in rats, determined by immunohistochemistry with monospecific antibody for OS or its active metabolite oseltamivir carboxylate (OC): A possibility of transporters dividing the drugs' excretion into the bile and kidney.Pharmacology research & perspectives · 2020Article
- Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position PaperIntensive care medicine · 2020Review
- Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic Modalities.Drug metabolism and disposition: the biological fate of chemicals · 2019Review
- Neuraminidase Inhibitors in Influenza Treatment and Prevention⁻Is It Time to Call It a Day?Viruses · 2018Article
- Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy.European journal of drug metabolism and pharmacokinetics · 2017Article
- The mechanisms of sudden-onset type adverse reactions to oseltamivir.Acta neurologica Scandinavica · 2017Review
- Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants.Drug metabolism and disposition: the biological fate of chemicals · 2017Article
- Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms.Basic & clinical pharmacology & toxicology · 2016Article
- Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.Biochemical pharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 2 countries.
Funding
Abstract
The effects of loading doses and probenecid coadministration on oseltamivir pharmacokinetics at four increasing dose levels in groups of eight healthy adult Thai volunteers (125 individual series) were evaluated. Doses of up to 675 mg were well-tolerated. The pharmacokinetics were dose linear. Oseltamivir phosphate (OS) was rapidly and completely absorbed and converted (median conversion level, 93%) to the active carboxylate metabolite. Median elimination half-lives (and 95% confidence intervals [CI]) were 1.0 h (0.9 to 1.1 h) for OS and 5.1 h (4.7 to 5.7 h) for oseltamivir carboxylate (OC). One subject repeatedly showed markedly reduced OS-to-OC conversion, indicating constitutionally impaired carboxylesterase activity. The coadministration of probenecid resulted in a mean contraction in the apparent volume of distribution of OC of 40% (95% CI, 37 to 44%) and a reduction in the renal elimination of OC of 61% (95% CI, 58 to 62%), thereby increasing the median area under the concentration-time curve (AUC) for OC by 154% (range, 71 to 278%). The AUC increase for OC in saliva was approximately three times less than the AUC increase for OC in plasma. A loading dose 1.25 times the maintenance dose should be given for severe influenza pneumonia. Probenecid coadministration may allow considerable dose saving for oseltamivir, but more information on OC penetration into respiratory secretions is needed to devise appropriate dose regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.